ALKERMES reported $4.44B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
ALKERMES USD 4.44B 42.4M Sep/2026
Amgen USD 96.05B 409M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Heron Therapeutics USD 230.45M 21.81M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Malin Corporation EUR 198.5M 70.1M Dec/2024
Merck USD 132.77B 2.97B Sep/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Otsuka Holdings JPY 4.32T 72.62B Sep/2026
Ovoca Bio EUR 2.07M 414K Dec/2025
Pfizer USD 204.54B 3.41B Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026